Floatz logo

Selinexor

DLBCL

Second Affiliated Hospital, School of Medicine, Zhejiang UniversitySmall moleculePhase 4 / ApprovedActive
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
61/ 100
Competitive Position
89/ 100

Competitive context

270 Active assets in the DLBCL cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
National Cancer Institute (NCI)
Phase 2/3A
Evomela
Ruijin Hospital
Phase 4BBB
Axicabtagene Ciloleucel
Ruijin Hospital
Phase 4BBB
FILGRASTIM
Ruijin Hospital
Phase 3BBB
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 3BBB

View all 50 →

Same molecule, other indications

Selinexor is also rated in:

mantle cell lymphomaDormant
BB
Indicative ·
70 / 100
View asset →
relapsed/refractory diffuse large B-cell lymphomaDormant
BB
Indicative ·
68 / 100
View asset →
pancreatic ductal adenocarcinomaDormant
B
Indicative ·
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →